Schlenk, R. F.
Weber, D.
Krzykalla, J.
Kindler, T.
Wulf, G.
Hertenstein, B.
Salih, H. R.
Südhoff, T.
Krauter, J.
Martens, U.
Wessendorf, S.
Runde, V.
Tischler, H. J.
Bentz, M.
Koller, E.
Heuser, M.
Thol, F.
Benner, A.
Ganser, A.
Döhner, K.
Döhner, H.
Funding for this research was provided by:
Deutsches Krebsforschungszentrum (DKFZ)
Article History
Received: 14 February 2023
Accepted: 4 September 2023
First Online: 8 September 2023
Competing interests
: Richard F. Schlenk: Consulting for or advisory board membership with Daiichi Sankyo, Pfizer, Astellas, and Novartis; research funding from PharmaMar, AstraZeneca, Pfizer, Roche, Boehringer Ingelheim, and Daiichi Sankyo; travel, accommodations, and expenses covered by Daiichi Sankyo. Hartmut Döhner: Consulting or advisory board: AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, Daiichi Sankyo, Gilead, Janssen, Jazz, Novartis, Servier, Syndax; Clinical Research Funding to Institution: AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis, Pfizer. Helmut R. Salih: Consulting for or advisory board membership with BMS, Celgene, Novartis, Pfizer, Roche, Synimmune GmbH; research funding from ABL Bio, Celgene, Novartis, Synimmune GmbH. Arnold Ganser: Consultant or advisory board: Celgene, JAZZ Pharmaceuticals, Novartis. Elisabeth Koller: Consulting or advisory board: AbbVie, Astellas, BMS, Celgene, Daiichi Sankyo, Jazz, Novartis, Servier, Pfizer. Felicitas Thol: Advisory Board for BMS, Abbvie, Takeda, Novartis, Pfizer. All others have declared no conflicts of interest.